Biosimilars in the management of neutropenia: focus on filgrastim

Désirée Caselli
Simone Cesaro
Maurizio Aricò

1Medical Department, Pediatric Unit, Azienda Sanitaria Provinciale Ragusa, Ragusa, 2Department of Pediatrics, Pediatric Hematology Oncology, Azienda Ospedaliera Universitaria Integrata, Verona, Italy

Abstract: Advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price may be a proportion of patients dying of complications due to treatment-induced infectious complications, such as neutropenia. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human granulocyte colony-stimulating factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce time and degree of neutropenia. A biosimilar is a copy of an approved original biologic medicine whose data protection has expired. The patent for filgrastim expired in Europe in 2006 and in the US in 2013. This review analyses the available evidence to be considered in order to design a strategy of use of G-CSF and its biosimilars. The clinical and safety outcomes of biosimilars are well within the range of historically reported data for originator filgrastim. This underscores the clinical effectiveness and safety of biosimilar filgrastim in daily clinical practice. Biosimilars can play an important role by offering the opportunity to reduce costs, thus contributing to the financial sustainability of treatment programs.

Keywords: neutropenia, filgrastim, biosimilars, G-CSF, fever, prophylaxis

Introduction

Recent advances in chemotherapy and surgery allows the majority of patients to survive cancer diseases. Yet, the price of intensified chemotherapy may be a proportion of patients dying of complications of major morbidities due to treatment-induced infectious complications. Indeed, cure may require neutropenia, which, although transient and reversible, may sometimes be so profound and prolonged as to cause episodes of persistent fever requiring hospitalization.²

Neutropenia may not only be more severe in patients undergoing induction therapy for acute leukemia, or in the preengraftment phase of hematopoietic stem cell transplantation, particularly allogeneic, but also in some patients receiving standard-dose chemotherapy for other neoplasms. With the aim of decreasing morbidity and mortality related to infectious complications, recombinant human granulocyte colony-stimulating factor (G-CSF), filgrastim, and pegylated filgrastim have been used to reduce time and degree of neutropenia.

Definitions

Neutropenia

The risk of infection rises as the neutrophil count falls below 500 µL⁻¹ and is most related to the number of circulating neutrophils. Although various definitions have
been reported, the most common is the presence of absolute neutrophil count of less than 500 µL⁻¹, or expected to decrease to <500 µL⁻¹ within the next 48 hours. Profound neutropenia is defined as an absolute neutrophil count <100 µL⁻¹.

**Fever**

In a neutropenic patient fever is a single episode of temperature >38.3°C (101.3°F) or a temperature >38°C (100.4°F) sustained for more than 1 hour. However, infection in neutropenic and immunocompromised patients may develop in the absence of fever, particularly in elderly or patients treated with corticosteroids.

**Granulocyte colony stimulating factors**

They are biological growth factors that promote the proliferation, differentiation, and activation of neutrophils in the bone marrow. GCSF works by reducing the transition time from stem cell to mature neutrophil, resulting in a larger number of functional and mature circulating neutrophils.

The most commonly used type of recombinant G-CSF is filgrastim.

**Strategy of use of G-CSF**

The risk of developing fever in patients treated with chemotherapy is the most important factor to determine the indication for prophylactic G-CSF. The risk is related to the intensity of chemotherapy, the presence and degree of injury to the gastrointestinal mucosa, the presence of underlying damage to the patient's hematopoietic stem cells, the concurrent use of radiation, and the overall clinical status of the patient (ie, age and comorbid conditions).

The use of G-CSF after the administration of chemotherapy may be different:

- **“Primary prophylaxis,”** when neutropenia is expected to occur following a course of chemotherapy, but the patient has never experienced it.
- **“Secondary prophylaxis,”** when the patient had a neutropenic fever in a previous course of similar chemotherapy and is thus expected to do so again.
- **“Supportive”** in the attempt to shorten the duration of severe chemotherapy-induced neutropenia in patients without fever (“afebrile neutropenia”).

Administration of G-CSF is generally not recommended for routine treatment in patients with established fever and neutropenia.

**Primary prophylaxis**

May be used to decrease neutropenic fever and days of hospitalization, but also to maintain dose-intense chemotherapy, if survival benefits may be achieved. The use of CSFs was suggested previously in those cases in which the incidence of the neutropenic fever after a given regimen was 40%. Recent guidelines suggest extending this use, inasmuch, they recommend primary prophylaxis when the anticipated incidence of neutropenic fever is in the range of 20% or higher with a given regimen, and no other equally safe and effective regimen not requiring CSF is available. This was based on randomized trials showing that primary prophylaxis was cost-effective when the risk of neutropenic fever with a specific regimen exceeded 20%.

Evidence from multiple randomized trials and meta-analyses supports the benefit of primary prophylaxis in reducing the frequency of hospitalization for antibiotic therapy, documented infection, and the rates of neutropenic fever in adults. The impact on survival (both short-term and long-term), and the effect in children, are less clear.

The continued use of primary G-CSF prophylaxis during all chemotherapy cycles is supported by a randomized trial in women receiving chemotherapy for breast cancer. The trial was closed prematurely after an interim analysis disclosing a higher rate of febrile neutropenia in the group receiving G-CSF during the first two cycles only (36% vs 10%).

American Society of Clinical Oncology guidelines recommend primary prophylaxis with CSFs for selected situations, such as patients aged 65 and older with diffuse aggressive lymphoma treated with curative chemotherapy, especially in the presence of comorbidities, or patients receiving dose-dense chemotherapy regimens that are supported by convincing efficacy data. Yet, the secondary — rather than primary — prophylaxis is preferred in all other conditions. Concerns are reported about the possible increase of pulmonary toxicity induced by the association of G-CSFs in patients with Hodgkin lymphoma receiving bleomycin. Yet, specific data are not available; toxicity is not reported with the same association in other types of cancer. Some clinical conditions may enhance the risk of adverse outcome, thus alleviating the choice to associate G-CSF (Table 1).

### Table 1 Risk factors for poor clinical outcomes of febrile neutropenia or infection

- Age more than 65 years
- Absolute neutrophil count <0.1/10³/L
- Neutropenia expected to last more than 10 days
- Invasive fungal infection
- All clinically documented infections (fungal infection, pneumonia, sepsis syndrome)
- Hospitalization at the time of fever
Secondary prophylaxis

Secondary prophylaxis is the administration of a G-CSF after a cycle complicated by a neutropenic fever episode. A prior episode of fever during neutropenia is a risk factor for developing fever during neutropenia in later cycles, with recurrences in 50%–60% of patients. This practice reduces the risk of a neutropenic fever by approximately one-half. The target is to maintain chemotherapy dose-intensity avoiding dose reduction; but a dose reduction may be the first therapeutic choice if the chemotherapy is not curative. No published regimen has ever shown improved disease-free or overall survival when secondary prophylaxis was instituted and the dose of chemotherapy maintained in any setting.

Treatment of patients with neutropenia

No role is established for G-CSFs in afebrile patients who developed severe neutropenia after chemotherapy. There is recommendation against their use, and also not to use G-CSFs routinely as an adjunct to antibiotics, except for patients who remain neutropenic and febrile after the initiation of antibiotics.

Side effects

Local reactions have included bruising and erythema at the injection site.

The use of growth factors is associated with a risk of general side effects, among which are fatigue (11%), generalized weakness (4%), and unspecified pain (2%). A common side effect is musculoskeletal and bone pain in ~22% of patients; transient hypotension has been reported, primarily associated with filgrastim intravenous administration. Chest pain was reported by 5% of patients receiving filgrastim following myelosuppressive chemotherapy. Transient increase in alkaline phosphatase and lactate dehydrogenase was reported in ~20% of patients receiving filgrastim following myelosuppressive chemotherapy. G-CSF-induced decreased bone mineral density was reported in a Washington University School of Medicine study in mice, as well as in children with severe chronic neutropenia receiving chronic treatment with filgrastim.

Since several hematopoietic and nonhematopoietic cell types express myeloid growth factor receptors, there has been a concern that certain malignant cell lineages might respond to therapy with a granulocyte colony stimulating factor (G-CSF), potentially worsening the underlying condition, or by triggering the development of malignancy in a susceptible individual. Because of this issue, the use of G-CSFs has been limited in patients undergoing induction therapy for acute myeloid leukemia. In a systematic review of 25 randomized trials of chemotherapy with or without G-CSF for a variety of neoplasms, although Acute myeloid leukemia/myelodysplastic syndrome was reported in significantly more patients treated with G-CSF, all-cause mortality was significantly lower in patients receiving chemotherapy with G-CSF, and greater reductions in mortality were observed in patients who received greater chemotherapy dose intensity. Thus, while the use of myeloid growth factors during chemotherapy might someway increase the risk of a therapy-related myeloid neoplasm, the absolute magnitude of the risk is small, and the risk is probably outweighed by the benefits of using CSFs in this setting.

A special mention should be made about patients with severe congenital neutropenia who benefit from long-lasting replacement therapy with G-CSF. In these subjects, a special propensity to develop acute myeloid leukemia/myelodysplastic
syndrome was reported, thus suggesting adapting the G-CSF schedule especially on long-lasting therapies.  

**Biosimilars in the treatment of neutropenia**

A biosimilar is a copy of an approved original biologic medicine whose data protection has expired.  

The patent for filgrastim expired in Europe in 2006 and in the US in 2013.  

Since the manufacturing processes remain proprietary, biosimilars are manufactured using independently developed proprietary process. Thus, the new biosimilar drug is a complex molecule of biological origin, produced with different methods, not chemically identical to the originator. It must be assessed more rigorously than generics, and thus not surprisingly the regulatory requirements of the European Medicines Agency (EMA) for the approval of biosimilars are more demanding.  

Biosimilars have to prove efficacy and safety comparable to the original product.  

On the other hand, biosimilars can play an important role by offering the opportunity to reduce costs, thus contributing to the financial sustainability of treatment programs.  

Concerns were raised among hematologists on the use of biosimilar G-CSF in stem cell transplant until sufficient efficacy and safety data have been collected. In response, several centers have initiated studies in neutropenic patients, in autologous and allogeneic transplantation. The results have shown the benefit of biosimilars for this indication, supporting the extrapolation by EMA.  

Available evidence for equivalence between biosimilar G-CSF and the originator products comprises identical or very similar amino-acid sequence and production in *Escherichia coli*, results of trials in patients and volunteers, in neutropenic patients, during autologous as well as allogeneic stem cell mobilization in adults and children.  

EMA has approved several biosimilar versions, three of which are commercially available (Table 2). In March 2015 came the first approval for a biosimilar in the US – Zarzio, Novartis’ copy of Amgen’s white blood cell-boosting product Neupogen (filgrastim). The drug is used to reduce the risk of infection during chemotherapy.  

Prophylaxis or treatment of febrile neutropenia with biosimilars is cost-efficient. In the absence of convincing evidence that pegfilgrastim is pharmacotherapeutically superior to standard filgrastim, there is no cost-efficiency rationale to treat with that drug.  

The clinical and safety outcomes are well within the range of historically reported data for originator filgrastim, underscoring the clinical effectiveness and safety of biosimilar filgrastim in daily clinical practice.

### Table 2 Approved G-CSF biosimilars

<table>
<thead>
<tr>
<th>Brand</th>
<th>Company</th>
<th>Approval date, note</th>
</tr>
</thead>
<tbody>
<tr>
<td>Filgrastim Ratiopharm</td>
<td>Ratiopharm</td>
<td>September 2008 but withdrawn from the EU market in July 2011</td>
</tr>
<tr>
<td>Ratiogranstim</td>
<td>Ratiopharm</td>
<td>September 2008</td>
</tr>
<tr>
<td>TevaGrastim</td>
<td>Teva Pharma</td>
<td>September 2008</td>
</tr>
<tr>
<td>Biogranstim</td>
<td>AbZ-Pharma GmbH</td>
<td>September 2008</td>
</tr>
<tr>
<td>Filgrastim Hexal</td>
<td>Hexal</td>
<td>February 2009</td>
</tr>
<tr>
<td>Zarzio</td>
<td>Sandoz</td>
<td>February 2009</td>
</tr>
<tr>
<td>Nivestim</td>
<td>Hospira</td>
<td>June 2010</td>
</tr>
<tr>
<td>Nivestim</td>
<td>Hospira Pty Ltd.</td>
<td>September 2010</td>
</tr>
<tr>
<td>Nivestim</td>
<td>Hospira NZ Ltd.</td>
<td>May 2012</td>
</tr>
<tr>
<td>Filgrastim BS Injection Syringe “Mochida”</td>
<td>Mochida/Fuji Pharma</td>
<td>November 2012</td>
</tr>
<tr>
<td>Filgrastim BS Injection Syringe “Nippon Kayaku”</td>
<td>Nippon Kayaku/Teva</td>
<td>March 2013</td>
</tr>
<tr>
<td>Zarzio</td>
<td>Sandoz Pty Ltd.</td>
<td>May 2013</td>
</tr>
<tr>
<td>Grastofil</td>
<td>Apotex Europe BV</td>
<td>October 2013</td>
</tr>
<tr>
<td>Zarzio</td>
<td>Novartis NZ Ltd.</td>
<td>March 2014</td>
</tr>
<tr>
<td>Filgrastim BS Injection Syringe “Sandoz”</td>
<td>Sandoz</td>
<td>March 2014</td>
</tr>
<tr>
<td>Accofil</td>
<td>Accord Healthcare Ltd.</td>
<td>September 2014</td>
</tr>
<tr>
<td>Zarzio</td>
<td>Sandoz</td>
<td>March 2015</td>
</tr>
</tbody>
</table>

**Disclosure**

The authors report no conflicts of interest in this work.

**References**


